TIMP-2 modulates cancer cell transcriptional profile and enhances E-cadherin/beta-catenin complex expression in A549 lung cancer cells

Oncotarget

Volumn 4, Issue 1, 2013, Pages 166-176

  Bourboulia, Dimitra ^a   Han, HuiYing ^a   Jensen Taubman, Sandra ^a   Gavil, Noah ^a,b   Isaac, Biju ^a,c   Wei, Beiyang ^a   Neckers, Len ^a   Stetler Stevenson, William G ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b BOWDOIN COLLEGE   (United States)

^c UNIVERSITY OF MIAMI   (United States)

Author keywords

Cell adhesion; E cadherin; Microarray analysis; TIMP 2; Tumor growth inhibition

Indexed keywords

ALANINE; BETA CATENIN; COMPLEMENTARY DNA; EPIDERMAL GROWTH FACTOR; MATRIX METALLOPROTEINASE; MUTANT PROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE 2; UVOMORULIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL ADHESION; CONTROLLED STUDY; DNA MICROARRAY; DOWN REGULATION; E CADHERIN GENE; ENZYME ACTIVITY; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IN VITRO STUDY; IN VIVO STUDY; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; METASTASIS; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; UPREGULATION;

EID: 84893378509     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.801     Document Type: Article

References (55)

1. Stetler-Stevenson WG and Yu AE. Proteases in invasion: matrix metalloproteinases. Semin Cancer Biol. 2001; 11(2):143-152.
2. Nguyen DX, Bos PD and Massague J. Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer. 2009; 9(4):274-284.
3. Kessenbrock K, Plaks V and Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell. 2010; 141(1):52-67.
4. Hernandez-Barrantes S, Bernardo M, Toth M and Fridman R. Regulation of membrane type-matrix metalloproteinases. Semin Cancer Biol. 2002; 12(2):131-138.
5. Strongin AY, Collier I, Bannikov G, Marmer BL, Grant GA and Goldberg GI. Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease. J Biol Chem. 1995; 270(10):5331-5338.
6. Albini A, Melchiori A, Santi L, Liotta LA, Brown PD and Stetler-Stevenson WG. Tumor cell invasion inhibited by TIMP-2. J Natl Cancer Inst. 1991; 83(11):775-779.
7. Imren S, Kohn DB, Shimada H, Blavier L and DeClerck YA. Overexpression of tissue inhibitor of metalloproteinases-2 retroviral-mediated gene transfer in vivo inhibits tumor growth and invasion. Cancer Res. 1996; 56(13):2891-2895.
8. DeClerck YA, Perez N, Shimada H, Boone TC, Langley KE and Taylor SM. Inhibition of invasion and metastasis in cells transfected with an inhibitor of metalloproteinases. Cancer Res. 1992; 52(3):701-708.
9. Seo DW, Li H, Guedez L, Wingfield PT, Diaz T, Salloum R, Wei BY and Stetler-Stevenson WG. TIMP-2 mediated inhibition of angiogenesis: an MMP-independent mechanism. Cell. 2003; 114(2):171-180.
10. Fernandez CA, Butterfield C, Jackson G and Moses MA. Structural and functional uncoupling of the enzymatic and angiogenic inhibitory activities of tissue inhibitor of metalloproteinase-2 (TIMP-2): loop 6 is a novel angiogenesis inhibitor. J Biol Chem. 2003; 278(42):40989- 40995.
11. Fernandez CA, Roy R, Lee S, Yang J, Panigrahy D, Van Vliet KJ and Moses MA. The anti-angiogenic peptide, loop 6, binds insulin-like growth factor-1 receptor. J Biol Chem. 2010; 285(53):41886-41895.
12. Bourboulia D, Jensen-Taubman S, Rittler MR, Han HY, Chatterjee T, Wei B and Stetler-Stevenson WG. Endogenous Angiogenesis Inhibitor Blocks Tumor Growth via Direct and Indirect Effects on Tumor Microenvironment. Am J Pathol. 2011; 179(5):2589-2600.
13. Stetler-Stevenson WG, Bourboulia D, Guedez L and Jensen-Taubman S. Anti-tumoral Properties of Endogenous Angiogenesis Inhibitors: A case for Continued TIMP-2 Preclinical Development. Current Angiogenesis. 2012; 1(2):148-156.
14. Lluri G, Langlois GD, McClellan B, Soloway PD and Jaworski DM. Tissue inhibitor of metalloproteinase-2 (TIMP-2) regulates neuromuscular junction development via a beta1 integrin-mediated mechanism. J Neurobiol. 2006; 66(12):1365-1377.
15. Lluri G, Langlois GD, Soloway PD and Jaworski DM. Tissue inhibitor of metalloproteinase-2 (TIMP-2) regulates myogenesis and beta1 integrin expression in vitro. Exp Cell Res. 2008; 314(1):11-24.
16. Oh J, Diaz T, Wei B, Chang H, Noda M and Stetler-Stevenson WG. TIMP-2 upregulates RECK expression via dephosphorylation of paxillin tyrosine residues 31 and 118. Oncogene. 2006; 25(30):4230-4234.
17. Oh J, Seo DW, Diaz T, Wei B, Ward Y, Ray JM, Morioka Y, Shi S, Kitayama H, Takahashi C, Noda M and Stetler-Stevenson WG. Tissue inhibitors of metalloproteinase 2 inhibits endothelial cell migration through increased expression of RECK. Cancer Res. 2004; 64(24):9062-9069.
18. Perez-Martinez L and Jaworski DM. Tissue inhibitor of metalloproteinase-2 promotes neuronal differentiation by acting as an anti-mitogenic signal. J Neurosci. 2005; 25(20):4917-4929.
19. Wingfield PT, Sax JK, Stahl SJ, Kaufman J, Palmer I, Chung V, Corcoran ML, Kleiner DE and Stetler-Stevenson WG. Biophysical and functional characterization of full-length, recombinant human tissue inhibitor of metalloproteinases-2 (TIMP-2) produced in Escherichia coli. Comparison of wild type and amino-terminal alanine appended variant with implications for the mechanism of TIMP functions. J Biol Chem. 1999; 274(30):21362-21368.
20. Bourboulia D and Stetler-Stevenson WG. Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs): Positive and negative regulators in tumor cell adhesion. Semin Cancer Biol. 2010; 20(3):161-168.
21. Bourboulia D, Jensen-Taubman S and Stetler-Stevenson WG. TIMP-2: An Endogenous Angiogenesis Inhibitor with Distinch Antitumoral Properties. Treatment Strategies -Hematology. 2012; 2(2):31-35.
22. Hu Y, Pioli PD, Siegel E, Zhang Q, Nelson J, Chaturbedi A, Mathews MS, Ro DI, Alkafeef S, Hsu N, Hamamura M, Yu L, Hess KR, Tromberg BJ, Linskey ME and Zhou YH. EFEMP1 suppresses malignant glioma growth and exerts its action within the tumor extracellular compartment. Mol Cancer. 2011; 10:123.
23. Durkin ME, Yuan BZ, Zhou X, Zimonjic DB, Lowy DR, Thorgeirsson SS and Popescu NC. DLC-1:a Rho GTPaseactivating protein and tumour suppressor. J Cell Mol Med. 2007; 11(5):1185-1207.
24. Strickland LA, Ross J, Williams S, Ross S, Romero M, Spencer S, Erickson R, Sutcliffe J, Verbeke C, Polakis P, van Bruggen N and Koeppen H. Preclinical evaluation of carcinoembryonic cell adhesion molecule (CEACAM) 6 as potential therapy target for pancreatic adenocarcinoma. J Pathol. 2009; 218(3):380-390.
25. Carraway RE and Plona AM. Involvement of neurotensin in cancer growth: evidence, mechanisms and development of diagnostic tools. Peptides. 2006; 27(10):2445-2460.
26. Cao H, Wang G, Meng L, Shen H, Feng Z, Liu Q and Du J. Association between Circulating Levels of IGF-1 and IGFBP-3 and Lung Cancer Risk: A Meta-Analysis. PLoS One. 2012; 7(11):e49884.
27. Bremnes RM, Veve R, Gabrielson E, Hirsch FR, Baron A, Bemis L, Gemmill RM, Drabkin HA and Franklin WA. High-throughput tissue microarray analysis used to evaluate biology and prognostic significance of the E-cadherin pathway in non-small-cell lung cancer. J Clin Oncol. 2002; 20(10):2417-2428.
28. Bremnes RM, Veve R, Hirsch FR and Franklin WA. The E-cadherin cell-cell adhesion complex and lung cancer invasion, metastasis, and prognosis. Lung Cancer. 2002; 36(2):115-124.
29. Rehbein G, Simm A, Hofmann HS, Silber RE and Bartling B. Molecular regulation of S100P in human lung adenocarcinomas. Int J Mol Med. 2008; 22(1):69-77.
30. Hida T, Yatabe Y, Achiwa H, Muramatsu H, Kozaki K, Nakamura S, Ogawa M, Mitsudomi T, Sugiura T and Takahashi T. Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res. 1998; 58(17):3761-3764.
31. Lin MI, Yu J, Murata T and Sessa WC. Caveolin-1-deficient mice have increased tumor microvascular permeability, angiogenesis, and growth. Cancer Res. 2007; 67(6):2849-2856.
32. Assadian S, El-Assaad W, Wang XQ, Gannon PO, Barres V, Latour M, Mes-Masson AM, Saad F, Sado Y, Dostie J and Teodoro JG. p53 inhibits angiogenesis by inducing the production of Arresten. Cancer Res. 2012; 72(5):1270-1279.
33. Acevedo LM, Barillas S, Weis SM, Gothert JR and Cheresh DA. Semaphorin 3A suppresses VEGF-mediated angiogenesis yet acts as a vascular permeability factor. Blood. 2008; 111(5):2674-2680.
34. Gerstel D, Wegwitz F, Jannasch K, Ludewig P, Scheike K, Alves F, Beauchemin N, Deppert W, Wagener C and Horst AK. CEACAM1 creates a pro-angiogenic tumor microenvironment that supports tumor vessel maturation. Oncogene. 2011; 30(41):4275-4288.
35. Wang D and DuBois RN. Cyclooxygenase 2-derived prostaglandin E2 regulates the angiogenic switch. Proc Natl Acad Sci U S A. 2004; 101(2):415-416.
36. Isogai C, Laug WE, Shimada H, Declerck PJ, Stins MF, Durden DL, Erdreich-Epstein A and DeClerck YA. Plasminogen activator inhibitor-1 promotes angiogenesis by stimulating endothelial cell migration toward fibronectin. Cancer Res. 2001; 61(14):5587-5594.
37. Tamagnone L. Emerging role of semaphorins as major regulatory signals and potential therapeutic targets in cancer. Cancer Cell. 2012; 22(2):145-152.
38. Moore CS and Crocker SJ. An Alternate Perspective on the Roles of TIMPs and MMPs in Pathology. Am J Pathol. 2012; 180(1):12-16.
39. Walsh LA, Cepeda MA and Damjanovski S. Analysis of the MMP-dependent and independent functions of tissue inhibitor of metalloproteinase-2 on the invasiveness of breast cancer cells. J Cell Commun Signal. 2012.
40. Murphy AN, Unsworth EJ and Stetler-Stevenson WG. Tissue inhibitor of metalloproteinases-2 inhibits bFGFinduced human microvascular endothelial cell proliferation. J Cell Physiol. 1993; 157(2):351-358.
41. Stetler-Stevenson WG. Tissue inhibitors of metalloproteinases in cell signaling: metalloproteinaseindependent biological activities. Sci Signal. 2008; 1(27):re6.
42. Ishiyama N, Lee SH, Liu S, Li GY, Smith MJ, Reichardt LF and Ikura M. Dynamic and static interactions between p120 catenin and E-cadherin regulate the stability of cellcell adhesion. Cell. 2010; 141(1):117-128.
43. Ceteci F, Ceteci S, Karreman C, Kramer BW, Asan E, Gotz R and Rapp UR. Disruption of tumor cell adhesion promotes angiogenic switch and progression to micrometastasis in RAF-driven murine lung cancer. Cancer Cell. 2007; 12(2):145-159.
44. Giehl K and Menke A. Microenvironmental regulation of E-cadherin-mediated adherens junctions. Front Biosci. 2008; 13:3975-3985.
45. Kase S, Sugio K, Yamazaki K, Okamoto T, Yano T and Sugimachi K. Expression of E-cadherin and beta-catenin in human non-small cell lung cancer and the clinical significance. Clin Cancer Res. 2000; 6(12):4789-4796.
46. Lu Z, Ghosh S, Wang Z and Hunter T. Downregulation of caveolin-1 function by EGF leads to the loss of E-cadherin, increased transcriptional activity of beta-catenin, and enhanced tumor cell invasion. Cancer Cell. 2003; 4(6):499-515.
47. Guilford P. E-cadherin downregulation in cancer: fuel on the fire? Mol Med Today. 1999; 5(4):172-177.
48. Jung YS, Liu XW, Chirco R, Warner RB, Fridman R and Kim HR. TIMP-1 induces an EMT-like phenotypic conversion in MDCK cells independent of its MMPinhibitory domain. PLoS One. 2012; 7(6):e38773.
49. Karamouzis MV and Papavassiliou AG. The IGF-1 network in lung carcinoma therapeutics. Trends Mol Med. 2006; 12(12):595-602.
50. Tang H, Liao Y, Chen G, Xu L, Zhang C, Ju S and Zhou S. Estrogen upregulates the IGF-1 signaling pathway in lung cancer through estrogen receptor-beta. Med Oncol. 2012.
51. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer. 2008; 8(12):915-928.
52. Badzio A, Wynes MW, Dziadziuszko R, Merrick DT, Pardo M, Rzyman W, Kowalczyk A, Singh S, Ranger-Moore J, Manriquez G, Gaire F, Jassem J and Hirsch FR. Increased insulin-like growth factor 1 receptor protein expression and gene copy number in small cell lung cancer. J Thorac Oncol. 2010; 5(12):1905-1911.
53. Dong A, Kong M, Ma Z, Qian J, Cheng H and Xu X. Knockdown of insulin-like growth factor 1 receptor enhances chemosensitivity to cisplatin in human lung adenocarcinoma A549 cells. Acta Biochim Biophys Sin (Shanghai). 2008; 40(6):497-504.
54. Dziadziuszko R, Merrick DT, Witta SE, Mendoza AD, Szostakiewicz B, Szymanowska A, Rzyman W, Dziadziuszko K, Jassem J, Bunn PA, Jr., Varella-Garcia M and Hirsch FR. Insulin-like growth factor receptor 1 (IGF1R) gene copy number is associated with survival in operable non-small-cell lung cancer: a comparison between IGF1R fluorescent in situ hybridization, protein expression, and mRNA expression. J Clin Oncol. 2010; 28(13):2174-2180.
55. Pollak M. Targeting insulin and insulin-like growth factor signalling in oncology. Curr Opin Pharmacol. 2008; 8(4):384-392.